louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04392687: The Study of Slip Pulse Feature Extraction Method Based on the Image Processing Technology for Traditional Chinese Medicine
Official title: The Study of Slip Pulse Feature Extraction Method Based on the Image Processing Technology for Traditional Chinese Medicine
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Alippery Pulse
Keywords: Wrist artery pulse diagnosis instrument
TCM pulse diagnosis
Feature extraction
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2020-05-19
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: primary care clinic

Brief summary: The diagnoses processes of Traditional Chinese Medicine (TCM) focus on the following four main types of diagnoses methods consisting of inspection, listening and smelling, inquiry, and palpation. The most important one is palpation also called pulse diagnosis which is to measure wrist artery pulse by TCM doctor's fingers to detect patient's health state. The pulse diagnosis has three parts, namely 'Cun', 'Guan' and 'Chi', with the location. Wrist measurements correspond to different parts of the body's organs.

However, the pulse information is analyzed by TCM doctor's pulse diagnoses process, which is picked only a single waveform from a long-term pulse measured process and often discarded the other waveforms contained in the same information, e.g. Slippery Pulse waveform. The research object of this project is to divide the TCM diagnosis patients into two groups, one is the Slippery Pulse group and the other is a Normal Pulse group, in which 30 cases are collected in each group. The purpose of this project will integrate the TCM doctor's experiences and standardize them in order to construct an effective Slippery Pulse diagnosis system. It could refine Slippery Pulse diagnoses processes and reduce their diagnoses loading by using the proposed approach during this project. Therefore, we could carry out the research on feature extraction method of Slippery Pulse based on the image processing technology. We could extract the pulse characteristics of Slippery Pulse automatically from the many measurement signals and improve the automatic judging ability of the current pulse instrument to the Slippery pulse waveform. Provide important pulse information to the TCM doctors as an important reference for clinical diagnoses.


Eligibility criteria: Inclusion Criteria:

1. Already sign test consent permit.
2. More than 20-year-old.

Exclusion Criteria:

1. Can not accept acupuncture points stimulators.
2. Allergic to acupuncture needles.

Primary outcomes:
measure: Slippery Pulse
timeFrame: 30 minutes in duration.
Secondary outcomes:
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: China Medical University Hospital
state: North District
Study officials:
References:
Clinical trial NCT03084887: Study of Tissue Expansion Devices Complications
Official title: Intervention Study of Common Complications About Patients Placed Tissue Expansion Devices
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Tissue Expansion
Keywords: Tissue Expansion Devices
Tissue Expansion
common complications
intervention study
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
Collaborators: name: First Affiliated Hospital Xi'an Jiaotong University
First posted: 2017-03-21
Enrollment: 208
Sex: ALL
Minimum age (years): 1
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Reduce the common complications incidence about patients placed tissue expansion devices to around 5%.

Detailed description: Study design： Randomized parallel controlled trial. Study comments: 1.Telephone follow-up trainment group about 2-3 months until secondary hospital. 2.Promote the health management manual of patient placed expander,which includes discharge list, injection list, expander affusion operation procedure, injection myth, you ask me answer,injection record, injection diary record, appointment diaries etc.

Eligibility criteria: Inclusion Criteria:

* aged 1-70 years male and female;
* no complication when inclusion;
* sign the informed consent.

Exclusion Criteria:

* joined other clinical trial;
* occurred complications before inclusion;
* other infectious diseases;
* the pregnant or lactating women.

Primary outcomes:
measure: incidence of patients suffered the common complications
timeFrame: 2-3 months until secondary hospital
Secondary outcomes:
Other outcomes:
Locations:
city: Xi'an
country: China
facility: xiaoling Wang
state: Shaanxi
Study officials:
affiliation: First Affiliated Hospital of Fourth Military Medical University
name: qing Yang, doctorate
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06971887: Feasibility Study of Use and Acceptability of New Clear Communication of Lab Test Results (CCLR) Letter for Older Adults
Official title: Embedding Health Literacy Best Practices: A Feasibility Study Using the Clear Communication of Laboratory Test Results (CCLR) Template
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Communication
Keywords: Health Literacy
Lab test results communication
Lead sponsor: University of Massachusetts, Worcester
Sponsor class: OTHER
First posted: 2025-05-14
Enrollment: 61
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: First 30 participants received standard of care; 2nd 30 participants received the CCLR templated result note
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study will try out a new way of writing a blood test result letter to patients explaining the results in a way to help them understand what the results mean and any next steps to be taken.

Detailed description: The primary goal of this study was to help healthcare providers more effectively communicate the meaning of laboratory test results and any need for follow-up, facilitating patient engagement in their healthcare. We propose that using an innovative laboratory test result template integrating health literacy best practices, specifically the Clear Communication of Lab Results (CCLR) template, has the potential to improve health outcomes and health care processes. The purpose of this study was to create and assess the feasibility of using the CCLR template for 3 common laboratory tests to increase knowledge and confidence, decrease anxiety, activate follow-up, and improve satisfaction among older adults.

Eligibility criteria: Inclusion Criteria:

* age 70 or older
* English fluency
* order for CBC, BMP, or FLP
* capacity to provide informed consent
* willingness to participate in follow-up phone survey

Exclusion Criteria:

* provider determined potential participant does not have cognitive capacity to read or understand communication about lab test results

Primary outcomes:
measure: Recruitment
timeFrame: 18 months
Secondary outcomes:
measure: Global Anxiety-Visual Scale
timeFrame: 2 weeks after blood test was drawn
measure: Confidence
timeFrame: 2 weeks after blood test was drawn
measure: Comprehension of follow-up plans
timeFrame: 2 weeks after blood test was drawn
measure: Patient Satisfaction
timeFrame: 2 weeks after blood test was drawn
Other outcomes:
Locations:
city: Worcester
country: United States
facility: University of Massachusetts Medical School
state: Massachusetts
Study officials:
affiliation: University of Massachusetts, Worcester
name: Nancy Morris, PhD, RN, ANP-BC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00300287: A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia
Official title: A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Diabetes Mellitus, Type 2
Keywords: Type 2 diabetes
Vildagliptin
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2006-03-08
Enrollment: 150
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is not being conducted in the United States. Key long-term clinical studies have shown that people with type 2 diabetes should try to achieve overall blood glucose levels as close to normal as possible. The purpose of this study is to gather data on the long-term safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar and whose blood glucose levels are close to normal.


Eligibility criteria: Inclusion Criteria:

* Completion of study CLAF237A2307 within 4 weeks of entering into the extension
* Written informed consent
* Ability to comply with all study requirements
* Blood glucose criteria must be met

Exclusion Criteria:

* Premature discontinuation from study CLAF237A2307

Primary outcomes:
measure: Change from baseline in HbA1c at 108 weeks
Secondary outcomes:
measure: Adverse event profile after 108 weeks of treatment
measure: Change in HbA1c from week 52 to week 108
measure: Change from baseline in fasting plasma glucose at week 108
measure: Change in fasting plasma glucose from week 52 to week 108
measure: Change from baseline in body weight at week 108
Other outcomes:
Locations:
city: Investigative Sites
country: Germany
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
citation: Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Wang Y, Dunning BE, Foley JE. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008 Nov;10(11):1114-24. doi: 10.1111/j.1463-1326.2008.00875.x. Epub 2008 Mar 18.
Clinical trial NCT02746887: Risk Factors Related to Metabolic Syndrome in School-aged Children Who Were Born Preterm
Official title: Risk Factors Related to Metabolic Syndrome in School-aged Children Who Were Born Preterm
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Metabolic Syndrome
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2016-04-21
Enrollment: 120
Sex: ALL
Minimum age (years): 8
Maximum age (years): 8
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. school aged children who were born preterm with a gestational age less than 32 weeks or a birth weight less than 1,500 g
2. school aged children who were born healthy term

Brief summary: This is a follow-up cohort study of 8 years old children born preterm at Seoul National University Children's Hospital in Korea from 2008-2009.

The children will visit outpatient clinics for examinations regarding growth, obesity and other risk factors related to metabolic syndrome.

The purpose of this study is to compare growth and risk factors of metabolic syndrome among children born preterm and children born healthy term at school age


Eligibility criteria: Inclusion Criteria:

* Very low birth weight infants and/or born less than 32 weeks of gestation age
* Healthy term infants for control group
* Parents and children accept of participation

Exclusion Criteria:

* Major congenital anomalies
* Neuromuscular disease
* Chromosomal anomalies
* Patients receiving growth hormone therapy
* Primary hypothyroidism

Primary outcomes:
measure: number of participants with abnormal laboratory values and/or abnormal physical status
timeFrame: at 8 years corrected age
Secondary outcomes:
measure: The number of participants with catch-up growth failure
timeFrame: at 8 years corrected age
measure: The number of participants with hypertension
timeFrame: at 8 years corrected age
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seung Han Shin
Study officials:
affiliation: Seoul National University Children's Hospital
name: Seung Han Y Shin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05181787: Biomarkers of Atrial Fibrillation Complicated With Stroke Based on Proteomics and Metabolomics
Official title: Biomarkers of Atrial Fibrillation Complicated With Stroke Based on Proteomics and Metabolomics
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Atrial Fibrillation
Stroke
Keywords: Atrial Fibrillation
Stroke
metabolomics
proteomics
Biomarkers
Lead sponsor: First Affiliated Hospital of Harbin Medical University
Sponsor class: OTHER
First posted: 2022-01-06
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The blood samples of patients with AF and patients with AF complicated with stroke were taken. The supernatant was centrifuged and put into - 80 ℃ refrigerator for storage.

Brief summary: Thrombus shedding in patients with atrial fibrillation (AF) can lead to cerebral artery embolism. Stroke caused by AF is very dangerous, which not only threatens the life of patients, but also seriously affects the quality of life. This study aims to explore the biomarkers of stroke in patients with AF by integrating proteomics and metabolomics data, and establish the network relationship of stroke in patients with AF, so as to reveal the molecular mechanism of stroke in patients with AF.


Eligibility criteria: Inclusion Criteria:

1. Age 18 years or above
2. Admission with atrial fibrillation or clinic visit for atrial fibrillation
3. Receive routine anticoagulant therapy;
4. Signing the consent form

Exclusion Criteria:

1. Pregnant women;
2. Lactating women;
3. Severe mitral stenosis;
4. Severe impairment of liver function;
5. Severe renal insufficiency;
6. Thyroid dysfunction requiring treatment.

Primary outcomes:
measure: Biomarkers of atrial fibrillation complicated with stroke based on proteomics and metabolomics
timeFrame: 1 day
Secondary outcomes:
measure: Quantitative changes of individual metabolites and proteins were calculated and graphed using the KEGG mapping tools.
timeFrame: 1 day
measure: By combining proteomics and metabolomics data, the investigators were able to identify the common pathways involved in AF with stroke.
timeFrame: 1 day
measure: All of the omics data were used to compare proteins/enzymes with metabolic pathways.
timeFrame: 1 day
Other outcomes:
Locations:
city: Harbin
country: China
facility: Yan
state: Heilongjiang
Study officials:
References:
Clinical trial NCT05883787: Development of a Technical Solution to Digitalize the Analysis of Failure and Effects.
Official title: Development of a Technical Solution to Digitalize the Analysis of Failure and Effects.
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Notification, Spousal
Lead sponsor: Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
Sponsor class: OTHER
First posted: 2023-06-01
Enrollment: 0
Sex: ALL
Minimum age (years): 0
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients in the Valencian community in Spain

Brief summary: This is a preliminar study to extract information from the data base of health inquiries from the Valencian community and to charge them in the analysis of modules and effects.


Eligibility criteria: Inclusion Criteria:

* To be a notification of a health inquiry

Exclusion Criteria:

* None

Primary outcomes:
measure: FMEA
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Alicante
country: Spain
facility: FISABIO
Study officials:
References:
Clinical trial NCT04720287: Ultrasound Guided Quadratus Lumborum Block Compared to Caudal Bupivacaine/ Neostigmine in Pediatric Lower Abdominal Surgeries
Official title: Ultrasound Guided Quadratus Lumborum Block Compared to Caudal Bupivacaine/ Neostigmine in Pediatric Lower Abdominal Surgeries, a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Postoperative Analgesia
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2021-01-22
Enrollment: 60
Sex: ALL
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of this study is to compare the postoperative pain control in children undergoing lower abdominal surgeries receiving QL block with those receiving caudal bupivacaine/ neostigmine.


Eligibility criteria: Inclusion Criteria:

* Patients American Society of Anesthesiologists physical status (ASA) I or II.
* Consent from parents or legal guardian(s).
* Lower abdominal surgeries.

Exclusion Criteria:

* Parents' refusal or legal guardian's refusal.

  * Infection at the injection site.
  * Known allergy to bupivacaine and/or neostigmine.
  * Contraindications to regional anesthesia (including coagulopathy and local infection).
  * Anatomical anomalies at the site of the block.

Primary outcomes:
measure: The total amount of paracetamol doses (mg)
timeFrame: 24 hours postoperatively
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain-Shams University Hospitals
Study officials:
References:
Clinical trial NCT01938287: SENSIMED Triggerfish in Closed Eyes
Official title: A Prospective, Open Label Study to Assess the 24-hour Intraocular Pressure Pattern Recorded With SENSIMED Triggerfish® in Healthy Subjects With Closed Eye
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Glaucoma
Lead sponsor: Sensimed AG
Sponsor class: INDUSTRY
First posted: 2013-09-10
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study investigates the effect of eye opening/closure on the quality of IOP (intraocular pressure) related patterns recorded with SENSIMED Triggerfish. Each subject receives 2 24-hour recording sessions, one with the recorded eye open and the other with the eye closed,using an ophthalmic patch.


Eligibility criteria: Inclusion Criteria:

* Healthy subject without previous ophthalmic medical history (except from indication for glasses)
* Aged ≥18 years, of either sex
* Have given written informed consent, prior to any investigational procedures

Exclusion Criteria:

* Patients with allergy to corneal anesthetic
* Patients with contraindications for silicone contact lens wear
* Patients not able to understand the character and individual consequences of the investigation
* Participation in other clinical research within the last 4 weeks

Primary outcomes:
measure: The difference between start and end TF (SENSIMED Triggerfish) in a closed eye as compared to the difference between start to end TF in an open eye
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: HUG, Department of Ophthalmology, Glaucoma Sector
Study officials:
References:
Clinical trial NCT02506387: Belgian Mitraclip Registry
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Mitral Valve Insufficiency
Lead sponsor: Universiteit Antwerpen
Sponsor class: OTHER
First posted: 2015-07-23
Enrollment: 200
Sex: ALL
Minimum age (years): 25
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with symptomatic severe mitral regurgitation at too high risk voor cardiac surgery and with suitable anatomy for mitraclip implantation

Brief summary: The primary objective of the registry is to investigate and follow all patients treated with the MitraClip System in Belgium. This information is intended to contribute to decision making with regards to MitraClip therapy selection in patients with mitral regurgitation: (a) by establishing the clinical value of the MitraClip therapy in the continuum of care; and (b) by providing practical information that will allow physicians to make therapeutic decisions, assist hospitals to make purchasing decisions, and assist insurers/government in making coverage decisions.

In addition national data will be shared with European registries in order to increase the knowledge about the efficacy of this new technique.


Eligibility criteria: Inclusion Criteria:

* severe mitral regurgitation
* symptomatic (NYHA class\>1) despite optimal medical therapy
* suitable anatomy for mitraclip implantation
* too high risk for cardiac surgery

Exclusion Criteria:

* \<1 year life expectancy

Primary outcomes:
measure: residual mitral regurgitation (MR) post mitraclip
timeFrame: at day 3-5 post mitraclip implantation
measure: cardiac mortality
timeFrame: 2 years
measure: surgical mitral valve intervention
timeFrame: 2 years
measure: hospitalization for heart failure
timeFrame: 2 years
Secondary outcomes:
measure: pericardial effusion
timeFrame: day 1-2 after mitraclip implantation
measure: change in New York Heart Association (NYHA) classification
timeFrame: 2 years
measure: distance during 6 min walking test
timeFrame: 1 year
measure: Left ventricular (LV) remodeling
timeFrame: 6 month
measure: Acute renal failure requiring dialysis
timeFrame: up to one month after mitraclip implantation
measure: urgent surgical mitral valve intervention
timeFrame: within 24h after procedure
measure: Change in Left ventricular ejection fraction (LVEF)
timeFrame: 6 month
Other outcomes:
Locations:
city: Edegem
country: Belgium
facility: University hospital Antwerp
state: Antwerp
city: Aalst
country: Belgium
facility: OLV Aalst
Study officials:
References: